{
    "eid": "2-s2.0-85072338061",
    "title": "Switching at low HIV-1 RNA into fixed dose combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/ EFV in first-line suppressed patients living with HIV",
    "cover-date": "2019-07-23",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "LMIC",
        "SALIF",
        "Single-Tablet-Regimen",
        "Treatment-emergent Resistance",
        "Virologically suppressed adults"
    ],
    "authors": [
        "Paula Munderi",
        "Edwin Were",
        "Anchalee Avihingsanon",
        "Pascale A.M. Mbida",
        "Lerato Mohapi",
        "Samba B. Moussa",
        "Marjolein Jansen",
        "Ceyhun Bicer",
        "Perry Mohammed",
        "Yvon van Delft"
    ],
    "citedby-count": 3,
    "ref-count": 48,
    "ref-list": [
        "Panel on antiretroviral guidelines for adults and adolescents",
        "CNS Toxicity of dolutegravir is not associated with psychiatric conditions or higher plasma exposure",
        "Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial",
        "Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial",
        "Simplification of antiretroviral therapy: A necessary step in the public health response to HIV/AIDS in resource-limited settings",
        "Safety, efficacy, and pharmacokinetics of rilpivirine: Systematic review with an emphasis on resource-limited settings",
        "Data on rilpivirine in treatment-na\u00efve patients. Lessons from Echo, thrive and Star",
        "Potential long-term cost savings in treatment of na\u00efve HIV-infected patients with rilpivirine/tenofovir/emtricitabine (single tablet regimen) in the Russian Federation. Value health",
        "Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- And middle-income countries",
        "Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy",
        "Improving first-line antiretroviral therapy in resource-limited settings",
        "Adult antiretroviral therapy guidelines 2017",
        "Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand",
        "Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials",
        "Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants",
        "Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF",
        "Rilpivirine vs. Efavirenz-based single-tablet regimens in treatment-naive adults: Week 96 efficacy and safety from a randomized phase 3b study",
        "A randomized switch from nevirapine-based antiretroviral therapy to single tablet rilpivirine/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed human immunodeficiency virus-1-infected Rwandans",
        "Pharmacokinetics of rilpivirine in HIV-infected pregnant women",
        "Substantially lower rilpivirine plasma concentrations during pregnancy",
        "Pharmacokinetics of total and unbound Rilpivirine in HIV-1\u2013infected pregnant women",
        "Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission",
        "SALIF trial: Switching suppressed first-line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option in LMICs",
        "Safety and efficacy of TDF/FTC/RPV and TDF/FTC/ EFV \u2013 48 week subgroup-analyses from the SALIF study",
        "Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel",
        "Viral suppression after 12 months of antiretroviral therapy in low- And middle-income countries: A systematic review",
        "Switching to coformulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort",
        "Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study",
        "HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009\u20132014",
        "Durability of RPV- And INSTI-based 1st-line regimens in HIV-infected patients starting ART with a VL <100 000 copies/mL: Data from the Icona Foundation study",
        "Rilpivirine use in the Swiss HIV cohort study: A prospective cohort study",
        "Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults",
        "The epi-TAF for tenofovir disoproxil fumarate?",
        "Phase III Sword 1&2: Switch to DTG+RPV maintains virologic suppression through 48 wks",
        "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection",
        "Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials",
        "Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Johannesburg",
            "@id": "60016218",
            "affilname": "University of the Witwatersrand, Johannesburg",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016218",
            "affiliation-country": "South Africa"
        },
        {
            "affiliation-city": "London",
            "@id": "60015879",
            "affilname": "Medical Research Council",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015879",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Douala",
            "@id": "123178620",
            "affilname": "Cabinet Medical IDOC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178620",
            "affiliation-country": "Cameroon"
        },
        {
            "affiliation-city": null,
            "@id": "123178472",
            "affilname": "Partners in Prevention",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178472",
            "affiliation-country": "Kenya"
        },
        {
            "affiliation-city": "Dakar",
            "@id": "123178306",
            "affilname": "Centre de Sant\u00e9 Gaspard KAMARA",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123178306",
            "affiliation-country": "Senegal"
        },
        {
            "affiliation-city": "Antwerpen",
            "@id": "120331258",
            "affilname": "BICER Consulting &amp; Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/120331258",
            "affiliation-country": "Belgium"
        },
        {
            "affiliation-city": "Breda",
            "@id": "118601347",
            "affilname": "Janssen-Cilag BV",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/118601347",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "High Wycombe",
            "@id": "113734673",
            "affilname": "Janssen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113734673",
            "affiliation-country": "United Kingdom"
        }
    ],
    "funding": [
        "Andrew Kambugu, Infectious Diseases Institute",
        "Bamrasnaradura Infectious Disease Institute",
        "Helen Joseph Hospital",
        "Janssen Pharmaceutica NV",
        "Janssen Pharmaceutical Companies of Johnson & Johnson and holds stock in Johnson & Johnson",
        "KAVI",
        "Karla Mellet, University of the Witwatersrand",
        "Kenyatta Hospital",
        "Netherlands Australia Thailand Research Collaboration, Bangkok",
        "Siriraj Hospital Department of Infectious Disease Faculty of Medicine, Bangkok",
        "Themba Lethu Research Centre",
        "UVRI Uganda Research Unit on AIDS, Entebbe",
        "Weerawat Manosuthi",
        "Yaound\u00e9 Central Hospital",
        "Aga Khan University",
        "MRC",
        "Makerere University"
    ]
}